Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Genomics Newborn Screening topic
No spam. Unsubscribe anytime.
Committee backs Sunshine Genetics Act to expand newborn genomic screening at Florida State
Summary
The committee reported CS/HB 907 favorably (25-0). The Sunshine Genetics Act would establish the Florida Institute for Pediatric Rare Diseases and authorize an opt‑in whole‑genome newborn screening program administered through Florida State University; supporters cited potential life‑saving diagnoses and projected Medicaid savings.
The Health and Human Services Committee unanimously advanced CS/HB 907, known as the Sunshine Genetics Act, which establishes the Florida Institute for Pediatric Rare Diseases and an opt‑in newborn whole‑genome sequencing program administered by Florida State University.
Representative Adam Anderson described the bill as creating an opt‑in newborn screening program that would expand screening beyond the roughly 60 conditions now included in Florida’s newborn panel to as many as 600 genetic conditions that have actionable treatments. Anderson told the committee the program would end much of the “diagnostic odyssey” many families face when a child has a rare genetic disorder.
Supporters included clinical and industry witnesses. Dr. Paul Kruschka, a clinical geneticist and GeneDX chief medical officer, described the results of the Guardian study and said expanded sequencing identified conditions standard screening would miss: “This is what expanded newborn screening can do.” He recounted a case—an infant diagnosed with spinal muscular atrophy who received gene therapy at two weeks of age and is now well—arguing that early detection made the treatment possible.
Anderson cited a $20 million startup investment estimate and a projected $80 million in health‑care savings based on a pilot project at a children’s hospital. Committee members asked no substantive questions recorded in the transcript. The committee voted 25-0 to report the bill favorably.
The bill creates the National Sunshine Genetics Consortium linking universities, children's hospitals, and industry, and directs FSU to administer the opt‑in sequencing program. Supporters said early diagnosis can enable available therapies and reduce long‑term costs; the sponsor and witnesses cited published pilot data showing several percent of screened newborns receiving diagnoses that would have been missed by standard screening.
The measure now moves forward to further legislative consideration.
